TFF Pharmaceuticals (TFFP) Stock Price, News & Analysis

Company Overview

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Key Stats

• Today's Range: $1.89 to $2.46
• 50-Day Range: $1.79 to $2.51
• 52-Week Range: $1.35 to $11.00
• Volume: 150,370 shs
• Average Volume: 111,757 shs
• Market Capitalization: $6.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Buy

TFF Pharmaceuticals Stock Analysis - MarketRank™

TFF Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

TFF Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

TFF Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TFF Pharmaceuticals are expected to grow in the coming year, from ($4.28) to ($3.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TFF Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TFF Pharmaceuticals is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TFF Pharmaceuticals has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.60% of the float of TFF Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

TFF Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TFF Pharmaceuticals has recently increased by 8.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TFF Pharmaceuticals does not currently pay a dividend.

Dividend Growth

TFF Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.60% of the float of TFF Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

TFF Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TFF Pharmaceuticals has recently increased by 8.68%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for TFFP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TFF Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.50% of the stock of TFF Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 15.25% of the stock of TFF Pharmaceuticals is held by institutions.

TFFP Stock Analysis - Frequently Asked Questions

How have TFFP shares performed this year?

TFF Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, TFFP shares have decreased by 71.9% and is now trading at $1.97.
View the best growth stocks for 2024 here.

How were TFF Pharmaceuticals' earnings last quarter?

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.22) EPS for the quarter, topping analysts' consensus estimates of ($1.70) by $0.48. The business had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.15 million. TFF Pharmaceuticals had a negative net margin of 1,612.73% and a negative trailing twelve-month return on equity of 225.15%.

When did TFF Pharmaceuticals' stock split?

Shares of TFF Pharmaceuticals reverse split on the morning of Tuesday, December 19th 2023. The 1-25 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did TFF Pharmaceuticals IPO?

TFF Pharmaceuticals (TFFP) raised $22 million in an IPO on Friday, October 25th 2019. The company issued 4,400,000 shares at $5.00 per share. National Securities served as the underwriter for the IPO.

How do I buy shares of TFF Pharmaceuticals?

Shares of TFFP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of TFF Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TFF Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), General Electric (GE), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/02/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TFFP
• CUSIP: N/A
• CIK: 1733413
• Web: www.tffpharma.com
• Phone: 817-438-6168
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $44.00
• High Stock Price Target: $44.00
• Low Stock Price Target: $44.00
• Potential Upside/Downside: +2,133.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,240,000.00
• Net Margins: -1,612.73%
• Pretax Margin: -1,612.81%
• Return on Equity: -225.15%
• Return on Assets: -170.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.63
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: $730,000.00
• Price / Sales: 9.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 3,470,000
• Free Float: 3,310,000
• Market Cap: $6.84 million
• Optionable: Optionable
• Beta: 1.32